Unlock instant, AI-driven research and patent intelligence for your innovation.

Anticoagulant compound, composition and application thereof

A compound and composition technology, applied in the field of new coumarin derivatives, can solve the problems of fast dissociation speed, unsatisfactory bioavailability, short half-life and the like

Active Publication Date: 2012-12-05
SHANGHAI SINE PHARMA LAB
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Oral platelet membrane II b / IIIa receptor antagonists have suboptimal bioavailability, short half-life, and rapid dissociation from the receptor

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anticoagulant compound, composition and application thereof
  • Anticoagulant compound, composition and application thereof
  • Anticoagulant compound, composition and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0078] 1, the preparation of 4-phenyl-3-buten-2-one (7)

[0079]

[0080] Benzaldehyde(6) SCR, AR, d=1.044 106.12 30.5ml 0.3mol 1 acetone SCR, AR, d=0.791 58.08 88ml 1.2mol 4 sodium hydroxide SCR, AR 40 120g 3mol 10 water distilled water 1.08L

[0081] Dissolve 120g of sodium hydroxide in 1.08L of distilled water to make a 10% aqueous solution of sodium hydroxide, cool in an ice bath to 5°C, add 30.5ml of benzaldehyde and 88ml of acetone, stir for 4 hours at 5~10°C, and perform thin-layer chromatography Shows complete reaction. The reaction solution was extracted three times with dichloromethane, and the organic layers were combined, washed with saturated aqueous ammonium chloride until neutral, and dried over anhydrous sodium sulfate overnight. After filtration, the filtrate was concentrated under reduced pressure to obtain a yellow oil. The crude product was distilled under reduced pressur...

Embodiment 2

[0087] SD rats were randomly divided into groups, 10 in each group, half male and half male. A negative control group was set up. Warfarin sodium was used as the positive control drug. 37 hours before the experiment, the drug was given by intragastric administration, the tail of the rat was cut off to collect blood, and the coagulation time was measured.

[0088] Test drug is dissolved in 0.5% CMC solution, and the consumption of embodiment 1 gained compound (2) is 1mg / kg, 3mg / kg, 10mg / kg, 30mg / kg, 100mg / kg; Positive control drug dosage is 1mg / kg. kg, 3mg / kg, 10mg / kg, 30mg / kg, the intragastric volume is 10ml / kg, single intragastric administration. The negative control group was given an equal volume of solvent.

[0089] The coagulation time was used as an index, and the t test was carried out to compare the significance of the difference between the groups.

[0090] See Table 1 for the rat coagulation time results of compound (2) obtained in the example.

[0091] The resu...

Embodiment 3

[0100] SD rats were randomly divided into groups, 4 in each group, half male and half male. A negative control group was set up. Warfarin sodium was used as the positive control drug. 37 hours before the experiment, the drug was given by intragastric administration, the tail of the rat was cut off to collect blood, and the coagulation time was measured.

[0101] The test drug was dissolved in 0.5% CMC solution, the compound (2) obtained in Example 1 and the positive control drug were both used in doses of 10 mg / kg, and the intragastric volume was 10 ml / kg for single intragastric administration. The negative control group was given an equal volume of solvent.

[0102] The coagulation time was used as an index, and the t test was carried out to compare the significance of the difference between the groups.

[0103] The results of coagulation time of test drugs in rats are shown in Table 3.

[0104] Table 3 Experimental results of tail-docking coagulation time in rats

[010...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a compound represented by a formula I or pharmaceutically acceptable salt thereof, a composition comprising the compound or the pharmaceutically acceptable salt thereof, and application of the compound or the pharmaceutically acceptable salt thereof and the composition in anti-coagulation medicaments.

Description

technical field [0001] The invention relates to an anticoagulant compound, in particular to a novel coumarin derivative. Background technique [0002] Coagulation disorders can lead to stroke, myocardial infarction and peripheral arterial obstructive disease and other diseases that seriously endanger human health. Although drugs such as heparin and oral coumarin are currently available for anticoagulation, the toxic and side effects of these drugs have always been a headache for clinical doctors. With the continuous advancement of basic medical research, people have gradually deepened their understanding of various enzymes, active factors and related receptors involved in the blood coagulation process. [0003] The following are several commonly used drugs for anticoagulant effects. [0004] Thrombin inhibitors. Thrombin is a serine protease that is a key enzyme in the coagulation cascade. Thrombin converts soluble fibrinogen to insoluble fibrin and activates coagulation...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07D209/48A61K31/4035A61P7/02
Inventor 陈良戴健张跃良沈康宁
Owner SHANGHAI SINE PHARMA LAB